Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Quizartinib + SGN-CD123A|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Quizartinib||Vanflyta|AC220||FLT3 Inhibitor 55 KIT Inhibitor 51 PDGFR-alpha Inhibitor 9 RET Inhibitor 39||Vanflyta (Quizartinib) targets both wild-type and mutant FLT3 containing activating internal tandem duplications, as well as PDGFRA, RET, and KIT, which may induce apoptosis and inhibit tumor growth (PMID: 19654408, PMID: 23497317).|
|SGN-CD123A||SGNCD123A|SGN CD123A||SGN-CD123A is an antibody-drug conjugate comprising a CD123-targeted antibody linked to pyrrolobenzodiazepine dimers, which delivers the DNA cross-linking agent agent to CD123-expressing tumor cells, potentially resulting in increased tumor cell death and decreased tumor growth (PMID: 29142066).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|